Grundläggande statistik
| LEI | 549300217EASRZ9JSF81 |
| CIK | 1553643 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Relmada Therapeutics, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| May 28, 2026 |
Exhibit 3.1 Name of entity as on file with the Nevada Secretary of State : RELMADA THERAPEUTICS, INC. Entity or Nevada Business Identification Number (NVID) : NV20121345551 1. Entity information Certificate to Accompany Restated Articles or Amended and Restated Articles Restated Articles - No amendments; articles are restated only and are signed by an officer of the corporation who has been author |
|
| May 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2026 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission F |
|
| May 13, 2026 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 Relmada Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File N |
|
| May 13, 2026 |
As filed with the Securities and Exchange Commission on May 13, 2026 As filed with the Securities and Exchange Commission on May 13, 2026 Registration No. |
|
| May 12, 2026 |
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update Exhibit 99.1 Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update ● Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a durable 80% CR rate at 12 months in the BCG-unresponsive |
|
| May 12, 2026 |
Exhibit 99.2 Unlocking Life Changing Therapies May 2026 C O R P O R A T E O V E R V I E W ©2026 R elm ada - Al l ri ghts r eserved Disclosures 2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2026 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission F |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55347 RELMADA THERAPEUTIC |
|
| April 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 9, 2026 |
Relmada Therapeutics, Inc. 33,685,096 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-294885 PROSPECTUS Relmada Therapeutics, Inc. 33,685,096 Shares of Common Stock This prospectus relates to the resale of up to 33,685,096 shares of Relmada Therapeutics, Inc. (the “Company,” “we,” “our,” or “us”) common stock, par value $0.001 per share (“common stock”), by the selling stockholders listed in this prospectus or their permitted tr |
|
| April 7, 2026 |
April 7, 2026 Sergio Traversa Chief Executive Officer Relmada Therapeutics, Inc. 2222 Ponce de Leon Blvd., Floor 3 Coral Gables, FL 33134 Re: Relmada Therapeutics, Inc. Registration Statement on Form S-3 Filed April 3, 2026 File No. 333-294885 Dear Sergio Traversa: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 reg |
|
| April 7, 2026 |
April 7, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 3, 2026 |
As filed with the Securities and Exchange Commission on April 3, 2026 As filed with the Securities and Exchange Commission on April 3, 2026 Registration No. |
|
| April 3, 2026 |
Exhibit 3.1(v) |
|
| April 3, 2026 |
Exhibit 3.1(vii) |
|
| April 3, 2026 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 Relmada Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Sto |
|
| April 3, 2026 |
CERTIFICATE OF CHANGE OF RELMADA THERAPEUTICS, INC. DATED AUGUST 4, 2015 Exhibit 3.1(vi) |
|
| March 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2026 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission |
|
| March 20, 2026 |
Exhibit 99.2 Exhibit 99.2 C O R P O R A T E O V E R V I E W Unlocking Life Changing Therapies March 2026 Disclosures The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward - looking statements made by us or on our behalf. This press release contains statements which constitute “forward - looking statements” within the meaning of Section 27A of the Securities Act of |
|
| March 20, 2026 |
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update Exhibit 99.1 Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update ● Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable safety profile ● Completed an oversubscribed $160 million PIPE financing led by lea |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55347 Relmada Therapeutics, Inc. (Exac |
|
| March 9, 2026 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 9, 2026, is entered into by and among Relmada Therapeutics, Inc., a Nevada corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms use |
|
| March 9, 2026 |
Exhibit 99.1 Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer ● Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBC ● BCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time ● Tolerability profile remains favorable – no ≥ Grade 3 treatment-related adverse e |
|
| March 9, 2026 |
RELMADA THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN |
|
| March 9, 2026 |
Exhibit 99.3 NDV - 01 12 - Month Phase 2 Data March 2026 ©2026 Relmada - All rights reserved Disclosures 2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward - looking statements made by us or on our behalf . This press release contains statements which constitute “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 an |
|
| March 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2026 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission |
|
| March 9, 2026 |
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing Exhibit 99.2 Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing CORAL GABLES, Fla., March 9, 2026 /GlobeNewswire/ - Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced that it has entered into a securitie |
|
| March 9, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 9, 2026, by and among Relmada Therapeutics, Inc., a Nevada corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and delivering t |
|
| January 30, 2026 |
Relmada Therapeutics, Inc. Up to $100,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-281877 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated April 28, 2025; and To Prospectus and Prospectus Supplement dated September 12, 2024) Relmada Therapeutics, Inc. Up to $100,000,000 Common Stock This prospectus supplement (this “Supplement”) amends and supplements certain information in our prospectus dated September 12, 2024 (the “B |
|
| December 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commiss |
|
| December 15, 2025 |
Exhibit 10.1 January 1, 2026 Sergio Traversa 650 NE 32 Street Unit 3804 Miami, FL 33137 Dear Mr. Traversa: Relmada Therapeutics, Inc. (the “Company”) desires to continue to employ you and to have the benefit of your skills and services. The parties entered into an Amended and Restated Employment Agreement on August 5, 2015 which is amended and restated herein. 1. Position. The terms of your positi |
|
| December 15, 2025 |
Exhibit 10.3 January 1, 2026 Maged Shenouda 9 James Street Montclair, NJ 07042 Dear Mr. Shenouda: On behalf of Relmada Therapeutics, Inc: (the “Company”), I am pleased to offer you the position of Chief Financial Officer. Speaking for myself, as well as the other members of the Board of Directors, we are all impressed with your credentials and look forward to your future success in this position. |
|
| December 15, 2025 |
Exhibit 10.2 January 1, 2026 Paul Kelly 122 Sevilla Avenue PH 14, Coral Gables, FL 33134 Dear Mr. Kelly: On behalf of Relmada Therapeutics, Inc: (the “Company”), I am pleased to offer you the position of Chief Operating Officer. Speaking for myself, as well as the other members of the Board of Directors, we are all impressed with your credentials and look forward to your future success in this pos |
|
| December 15, 2025 |
Exhibit 10.4 January 1, 2026 Charles Ence 5861 S Albion Ct Greenwood Village, CO 80121 Dear Mr. Ence: On behalf of Relmada Therapeutics, Inc: (the “Company”), I am pleased to offer you the position of Chief Accounting and Compliance Officer. Speaking for myself, as well as the other members of the Board of Directors, we are all impressed with your credentials and look forward to your future succes |
|
| November 13, 2025 |
Exhibit 99.2 |
|
| November 13, 2025 |
Exhibit 99.1 Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Secured FDA alignment on key elements of Phase 3 program with two independent paths for appro |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commiss |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000- 55347 RELMADA THERAP |
|
| November 5, 2025 |
RELMADA THERAPEUTICS, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Exhibit 4.1 RELMADA THERAPEUTICS, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [●] (subject to adjustment) Warrant No. [●] Original Issue Date: [●], 2025 Relmada Therapeutics, Inc., a Nevada corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●] or its registered assigns (the “ |
|
| November 5, 2025 |
Exhibit 99.1 Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants CORAL GABLES, Fla., November 4, 2025 /PRNewswire/ - Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the pric |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissi |
|
| November 5, 2025 |
Exhibit 1.1 40,142,000 Shares and Pre-Funded Warrants to Purchase 5,315,000 Shares RELMADA THERAPEUTICS, INC. UNDERWRITING AGREEMENT November 4, 2025 JEFFERIES LLC LEERINK PARTNERS LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o LEERINK PARTNERS LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 Ladies and Gentlemen: Int |
|
| November 5, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-281877 PROSPECTUS SUPPLEMENT (to Prospectus dated September 12, 2024) 40,142,000 Shares of Common Stock Pre-Funded Warrants to Purchase 5,315,000 Shares of Common Stock 5,315,000 Shares of Common Stock Underlying the Pre-Funded Warrants We are offering 40,142,000 shares of our common stock and, in lieu of shares of common stock to investors tha |
|
| November 4, 2025 |
Exhibit 99.2 Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a registrational trial in 2nd line refractory BCG-unresponsive NMIBC, and 2) a randomized controlled trial in interme |
|
| November 4, 2025 |
Issuer Free Writing Prospectus dated November 4, 2025 Filed Pursuant to Rule 433 Registration No. |
|
| November 4, 2025 |
Exhibit 99.1 Unlocking Life Changing Therapies October 2025 C O R PO R AT E O VER VI E W ©2025 Relmada - All rights reserved Disclosures The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward - looking statements made by us or on our behalf . This press release contains statements which constitute “forward - looking statements” within the meaning of Section 27 A of |
|
| November 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissi |
|
| September 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commis |
|
| September 17, 2025 |
Exhibit 99.1 Unlocking Life Changing Therapies September 2025 C O R PO R AT E O VER VI E W ©2025 Relmada - All rights reserved Disclosures 2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward - looking statements made by us or on our behalf . This press release contains statements which constitute “forward - looking statements” within the meaning of Section 27 |
|
| September 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commis |
|
| September 16, 2025 |
Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement CORAL GABLES, FL – September 16, 2025 (GlobeNewswire) – Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today announced that on September 15, 2025 it received writt |
|
| September 10, 2025 |
Exhibit 99.2 Unlocking Life Changing Therapies August 2025 C O R PO R AT E O VER VI E W ©2025 Relmada - All rights reserved Disclosures 2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward - looking statements made by us or on our behalf . This press release contains statements which constitute “forward - looking statements” within the meaning of Section 27 A o |
|
| September 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commis |
|
| September 10, 2025 |
Relmada Issues Mid-Year CEO Letter to Shareholders Exhibit 99.1 Relmada Issues Mid-Year CEO Letter to Shareholders CORAL GABLES, FL – Sep 10, 2025 (GlobeNewswire) – Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today issued a Letter to Shareholders from Sergio Traversa, Chief Executive Officer. |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissio |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000 - 55347 RELMADA THERAPEUTI |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission |
|
| August 7, 2025 |
Exhibit 99.2 Unlocking Life Changing Therapies August 2025 CORPORATE OVERVIEW ©202 5 Relmada - All rights reserve d Disclosures 2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward - looking statements made by us or on our behalf . This press release contains statements which constitute “forward - looking statements” within the meaning of Section 27 A of the Se |
|
| August 7, 2025 |
Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC 6-month follow-up for NDV-01 showed a 91% overall response rate at any time in non-muscle invasive bladder cancer, with good overall safety Enrollment in the Phase 2 study for NDV-01 continues, with updates expected at 9 and 12 month data follow-u |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission F |
|
| June 18, 2025 |
Exhibit 99.1 June 17, 2025 Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology Dr. Pruthi brings vast clinical development experience advancing novel therapies for NMIBC to Relmada and the NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., June 17, 2025 (GLOBE NEWSWIRE) - Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Com |
|
| June 18, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission |
|
| June 13, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Relmada Therapeutics, Inc. |
|
| June 13, 2025 |
Relmada Therapeutics, Inc. 2021 Equity Incentive Plan, as amended Exhibit 99.3 Relmada Therapeutics, Inc. 2021 EQUITY INCENTIVE PLAN (AS AMENDED) As adopted by the Board of Directors of Relmada Therapeutics, Inc., on March 19, 2021. As approved by the shareholders of Relmada Therapeutics, Inc., on May 20, 2021. As amended by the Board of Directors of Relmada Therapeutics, Inc., March 18, 2022. As approved by the shareholders of Relmada Therapeutics, Inc., on May |
|
| June 13, 2025 |
As filed with the Securities and Exchange Commission on June 12, 2025 As filed with the Securities and Exchange Commission on June 12, 2025 Registration No. |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission F |
|
| May 12, 2025 |
Letter from Marcum LLP dated May 12, 2025 EXHIBIT 16.1 May 12, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Relmada Therapeutics, Inc. under Item 4.01 of its Form 8-K dated May 8, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Relmada Therapeutics, Inc. conta |
|
| May 12, 2025 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 12, 2025 |
Exhibit 10.2 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain portions of this exhibit indicated by [REDACTED] have been omitted because the Registrant customarily and actually treats that information as private or confidential and the omitted information is not material. EXCLUSIVE LICENSE AGREEMENT THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into effective as of March |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55347 RELMADA THERAPEUTIC |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission |
|
| April 28, 2025 |
Relmada Therapeutics, Inc. Up to $7,976,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-281877 PROSPECTUS SUPPLEMENT (To Prospectus and Prospectus Supplement dated September 12, 2024) Relmada Therapeutics, Inc. Up to $7,976,000 Common Stock This prospectus supplement (this “Sticker Supplement”) amends and supplements certain information in our prospectus dated September 12, 2024 (the “Base Prospectus”), as supplemented by our pros |
|
| April 28, 2025 |
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 Exhibit 99.1 Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release “GEM/DOCE” formulation* NDV-01 showed promising clinical activity in BCG-naïve and BCG-unresponsive patients, with favorable overall tolerability Data to be revie |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55347 Relmada Therapeutics, Inc. (Exac |
|
| March 27, 2025 |
Exhibit 99.1 Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in April Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in other compulsion-related disorder |
|
| March 27, 2025 |
Clawback Policy, effective November 21, 2023. Exhibit 97.1 Relmada Therapeutics, Inc. CLAWBACK POLICY (As adopted by the Board of Directors on November 21, 2023) 1. Introduction and Purpose 1.1 Introduction. This document sets forth the Clawback Policy (the “Policy”) of Relmada Therapeutics, Inc. (the “Company,” which term as used in this Policy, unless the context otherwise requires, shall include its subsidiaries). 1.2 Purpose. The Company |
|
| March 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission |
|
| March 27, 2025 |
Insider Trading Policy, effective November 10, 2020. Exhibit 19.1 RELMADA THERAPEUTICS, INC. Insider Trading COMPLIANCE POLICY Relmada Therapeutics, Inc., a Nevada corporation (the “Company”) prohibits: ● insider trading in the Company’s securities ( “Securities”)1; and ● the unauthorized disclosure of the Company’s confidential information that might enable others to engage in insider trading in the Securities. The Company adopted this Insider Trad |
|
| March 26, 2025 |
Exhibit 99.1 Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 patients, with ~62,000 newly diagnosed patients annually) Topline efficacy and safety Phase |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission |
|
| February 6, 2025 |
Exhibit 99.1 Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB Phase 2a results signaled improvement in Tourette symptoms, quality of life and robust overall safety, supporting Sepranolone as a n |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissi |
|
| February 6, 2025 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”. ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (“Agreement”), dated February 3, 2025 (the “Effect |
|
| January 27, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissi |
|
| January 6, 2025 |
Exhibit 10.7 Retention Compensation Agreement This Retention Compensation Agreement (the “Agreement”) is made and entered into as of August 27, 2024 by and between Charles Ence (“Employee”) and Relmada Therapeutics, Inc. (“Company”). WHEREAS, the Company recognizes the value of the Employee’s contributions and wishes to incentivize the Employee to remain with the Company; WHEREAS, the Employee ack |
|
| January 6, 2025 |
Exhibit 10.2 January 1, 2025 Sergio Traversa 650 NE 32 Street Unit 3804 Miami, FL 33137 Dear Mr. Traversa: Relmada Therapeutics, Inc. (the “Company”) desires to continue to employ you and to have the benefit of your skills and services. The parties entered into an Amended and Restated Employment Agreement on August 5, 2015 which is amended and restated herein. 1. Position. The terms of your positi |
|
| January 6, 2025 |
Exhibit 10.4 January 1, 2025 Charles Ence 5861 S Albion Ct Greenwood Village, CO 80121 Dear Mr. Ence: On behalf of Relmada Therapeutics, Inc: (the “Company”), I am pleased to offer you the position of Chief Accounting and Compliance Officer. Speaking for myself, as well as the other members of the Board of Directors, we are all impressed with your credentials and look forward to your future succes |
|
| January 6, 2025 |
Exhibit 10.5 Retention Compensation Agreement This Retention Compensation Agreement (the “Agreement”) is made and entered into as of August 27, 2024 by and between Sergio Traversa (“Employee”) and Relmada Therapeutics, Inc. (“Company”). WHEREAS, the Company recognizes the value of the Employee’s contributions and wishes to incentivize the Employee to remain with the Company; WHEREAS, the Employee |
|
| January 6, 2025 |
Exhibit 10.3 January 1, 2025 Maged Shenouda 9 James Street Montclair, NJ 07042 Dear Mr. Shenouda: On behalf of Relmada Therapeutics, Inc: (the “Company”), I am pleased to offer you the position of Chief Financial Officer. Speaking for myself, as well as the other members of the Board of Directors, we are all impressed with your credentials and look forward to your future success in this position. |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2025 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissio |
|
| January 6, 2025 |
Exhibit 10.8 Retention Compensation Agreement This Retention Compensation Agreement (the “Agreement”) is made and entered into as of August 27, 2024 by and between Paul Kelly (“Consultant”) and Relmada Therapeutics, Inc. (“Company”). WHEREAS, the Company recognizes the value of the Employee’s contributions and wishes to incentivize the Employee to remain with the Company; WHEREAS, the Employee ack |
|
| January 6, 2025 |
Exhibit 10.1 January 1, 2025 Paul Kelly 122 Sevilla Avenue PH 14, Coral Gables, FL 33134 Dear Mr. Kelly: On behalf of Relmada Therapeutics, Inc: (the “Company”), I am pleased to offer you the position of Chief Operating Officer. Speaking for myself, as well as the other members of the Board of Directors, we are all impressed with your credentials and look forward to your future success in this pos |
|
| January 6, 2025 |
Exhibit 10.6 Retention Compensation Agreement This Retention Compensation Agreement (the “Agreement”) is made and entered into as of August 27, 2024 by and between Maged Shenouda (“Employee”) and Relmada Therapeutics, Inc. (“Company”). WHEREAS, the Company recognizes the value of the Employee’s contributions and wishes to incentivize the Employee to remain with the Company; WHEREAS, the Employee a |
|
| December 9, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissi |
|
| December 9, 2024 |
Exhibit 99.1 Relmada Therapeutics to discontinue the Reliance II and Relight Phase 3 studies of REL-1017 Relmada Therapeutics has commenced a process to explore strategic alternatives to maximize shareholder value CORAL GABLES, FL, December 9, 2024 (GLOBENEWSWIRE) - Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the ce |
|
| December 4, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissi |
|
| December 4, 2024 |
Exhibit 99.1 Relmada Therapeutics Reports that Data Monitoring Committee (DMC) assessment indicates that the Phase 3 Reliance II trial is futile at its interim analysis and is unlikely to meet the primary efficacy endpoint with statistical significance The DMC did not identify any new safety concerns Relmada to evaluate potential next steps for the REL-1017 program Relmada to continue to focus on |
|
| November 14, 2024 |
RLMD / Relmada Therapeutics, Inc. / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-rlmd093024a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Relmada Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 75955J402 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000- 55347 RELMADA THERAP |
|
| September 11, 2024 |
Relmada Therapeutics, Inc. 2222 Ponce de Leon Blvd., Floor 3 Coral Gables, FL 33134 (786) 629-1376 Relmada Therapeutics, Inc. 2222 Ponce de Leon Blvd., Floor 3 Coral Gables, FL 33134 (786) 629-1376 September 11, 2024 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Re: Relmada Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-281877 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under t |
|
| September 6, 2024 |
September 6, 2024 Sergio Traversa Chief Executive Officer Relmada Therapeutics, Inc. |
|
| August 30, 2024 |
As filed with the Securities and Exchange Commission on August 30, 2024 As filed with the Securities and Exchange Commission on August 30, 2024 Registration No. |
|
| August 30, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-3 Registration Statement under the Securities Act of 1933 (Form Type) Relmada Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price per Unit (3) Maximum Aggregate Offering Price Fee Rate Amount of Re |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000 - 55347 Relmada Therapeuti |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission F |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55347 RELMADA THERAPEUTIC |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 19, 2024 |
Exhibit 99.1 Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results CORAL GABLES, Fla., Mar 19, 2024 /PRNewswire/ - Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results f |
|
| March 19, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number: 000-55347 Relmada Therapeutics, Inc. (Exact name of registrant as specified in its c |
|
| March 6, 2024 |
EX-99.1 2 d735262dex991.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date:March 6, 2024 |
|
| March 6, 2024 |
RLMD / Relmada Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Relmada Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 75955J 402 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| February 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Relmada Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 75955J402 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pur |
|
| February 14, 2024 |
RLMD / Relmada Therapeutics, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
RLMD / Relmada Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01806-relmadatherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Relmada Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 75955J402 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissio |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissio |
|
| January 4, 2024 |
Exhibit 99.1 Relmada Therapeutics Provides Corporate Update Company Well-Positioned for a Pivotal 2024 with Multiple Key Clinical Development Milestones Anticipated Relmada’s Strong Balance Sheet to Support the Company Through All of 2024’s Expected Critical Catalysts CORAL GABLES, Fla., January 4, 2024 /PRNewswire/ - Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company ad |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissio |
|
| November 8, 2023 |
Relmada Therapeutics, Inc. Condensed Consolidated Balance Sheets Exhibit 99.1 Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results CORAL GABLES, Fla., November 8, 2023 /PRNewswire/ - Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the thir |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissi |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000- 55347 RELMADA THERAP |
|
| October 11, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2023 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissi |
|
| October 11, 2023 |
Exhibit 99.1 Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023 - Low-dose psilocybin generated statistically significant reductions in liver fat content, plasma glucose levels and body weight gain in a mice model with high-fat-high-fructose diet (HFHFD)-induced metabolic dysfunction-associated steatotic liver disease (MASLD) without det |
|
| October 10, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissi |
|
| October 10, 2023 |
Exhibit 99.1 Targeting Major Advances in the Treatment of CNS Disorders October 10 th , 2023 ©2023 Relmada - All rights reserved D i sc lo s u r es 2 Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc . (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forwa |
|
| October 4, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissio |
|
| October 4, 2023 |
Exhibit 99.1 Targeting Major Advances in the Treatment of CNS Disorders October 4 th , 2023 ©2023 Relmada - All rights reserved Disclosures 2 Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc . (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward - loo |
|
| September 20, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commis |
|
| September 20, 2023 |
Exhibit 99.1 September 20, 2023 Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder ● Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment ● Long-term dosing with REL-1017 was well-tolera |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commiss |
|
| August 10, 2023 |
Exhibit 99.1 Targeting Major Advances in the Treatment of CNS Disorders August 10 th , 2023 ©2023 Relmada - All rights reserved Disclosures 2 Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward - look |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissio |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000 - 55347 Relmada Therapeuti |
|
| August 8, 2023 |
Relmada Therapeutics, Inc. Condensed Consolidated Balance Sheets Exhibit 99.1 Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results CORAL GABLES, Fla., August 8, 2023 /PRNewswire/ - Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the secon |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission |
|
| July 7, 2023 |
RLMD / Relmada Therapeutics Inc / BlackRock Inc. Passive Investment us75955j4022070723.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) RELMADA THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 75955J402 - (CUSIP Number) June 30, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| June 21, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Relmada Therapeutics, Inc. |
|
| June 21, 2023 |
As filed with the Securities and Exchange Commission on June 21, 2023 As filed with the Securities and Exchange Commission on June 21, 2023 Registration No. |
|
| May 25, 2023 |
Exhibit 10.1 Relmada Therapeutics, Inc. 2021 EQUITY INCENTIVE PLAN (AS AMENDED) As adopted by the Board of Directors of Relmada Therapeutics, Inc., on March 19, 2021. As approved by the shareholders of Relmada Therapeutics, Inc., on May 20, 2021. As amended by the Board of Directors of Relmada Therapeutics, Inc., March 18, 2022. As approved by the shareholders of Relmada Therapeutics, Inc., on May |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission F |
|
| May 15, 2023 |
Exhibit 99.1 Targeting Major Advances in the Treatment of CNS Disorders May 15 th , 2023 ©202 3 Relmada - All rights reserve d Disclosures 2 Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward - looki |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission F |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission F |
|
| May 11, 2023 |
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results Exhibit 99.1 Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results CORAL GABLES, Fla., May 11, 2023 /PRNewswire/ - Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first qu |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55347 RELMADA THERAPEUTIC |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2023 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission |
|
| April 19, 2023 |
Exhibit 99.1 Targeting Major Advances in the Treatment of CNS Disorders April 19th, 2023 ©2023 Relmada - All rights reserved Disclosures 2 Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward - looking |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Commission file number: 000-55347 Relmada Therapeutics, Inc. (Exact name of registrant as specified in its c |
|
| March 23, 2023 |
Relmada Therapeutics, Inc. Consolidated Balance Sheets Exhibit 99.1 Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results CORAL GABLES, Fla., Mar 23, 2023 /PRNewswire/ - Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results f |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| February 14, 2023 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Relmada Therapeutics, Inc. (Title of Class of Securities) Common Stock, par value $0. |
|
| February 14, 2023 |
RLMD / Relmada Therapeutics Inc / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm233474-29sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* RELMADA THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (the “Shares |
|
| February 14, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Relmada Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 75955J402 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pur |
|
| February 14, 2023 |
RLMD / Relmada Therapeutics Inc / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-rlmd123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Relmada Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 75955J402 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) C |
|
| February 14, 2023 |
RLMD / Relmada Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236221d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Relmada Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 75955J402 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Stateme |
|
| February 14, 2023 |
SC 13G/A 1 sc13ga107422rlmd02142023.htm AMENDMENT NO. 1 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Relmada Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0 |
|
| February 9, 2023 |
RLMD / Relmada Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Relmada Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 75955J402 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) |
|
| February 1, 2023 |
RLMD / Relmada Therapeutics Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us75955j4022020123.txt us75955j4022020123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) RELMADA THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 75955J402 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2023 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissi |
|
| January 17, 2023 |
RELMADA THERAPEUTICS, INC. 2222 Ponce De Leon Blvd., 3rd Floor Coral Gables, FL 33134 Exhibit 99.1 RELMADA THERAPEUTICS, INC. 2222 Ponce De Leon Blvd., 3rd Floor Coral Gables, FL 33134 January 12, 2023 Fabiana Fedeli c/o Relmada Therapeutics, Inc. 2222 Ponce De Leon Blvd., 3rd Floor Coral Gables, FL 33134 Dear Ms. Fedeli: On behalf of Relmada Therapeutics, Inc. (the “Company”), I would like to welcome you to our team. I would also like to take this time to confirm our discussions w |
|
| January 17, 2023 |
Exhibit 99.2 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) effective this 12th day of January, 2023, by and between Relmada Therapeutics, Inc., a Nevada corporation (the “Corporation”), and Fabiana Fedeli (“Indemnitee”). RECITALS WHEREAS, the Corporation, which is organized under the Nevada Revised Statutes (the “NRS”), wishes to enter into this Agreement to set forth |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissio |
|
| January 9, 2023 |
Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O’Gorman MD as Chief Medical Officer EX-99.1 2 ea171401ex99-1relmada.htm PRESS RELEASE ISSUED ON JANUARY 9, 2023 Exhibit 99.1 Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O’Gorman MD as Chief Medical Officer CORAL GABLES, Fla., January 9, 2023 /PRNewswire/ - Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointm |
|
| January 9, 2023 |
Exhibit 99.2 Targeting Major Advances in the Treatment of CNS Disorders January 9, 2023 EXHIBIT 99.2 ©2023 Relmada - All rights reserved Disclosures 2 Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forwa |
|
| January 5, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2023 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissio |
|
| January 5, 2023 |
Exhibit 10.1 ADVISORY AGREEMENT This ADVISORY AGREEMENT (this ?Agreement?) is made and entered into as of January 1, 2023 (the ?Effective Date?), by and between Relmada Therapeutics, Inc., a Nevada corporation (the ?Company?), and Paul Kelly (the ?Advisor?). RECITALS: A. The Company is a late-stage biotechnology company addressing diseases of the central nervous system, with a focus on major depre |
|
| December 28, 2022 |
EXHIBIT 10.1 AMENDMENT NO. 2 TO LICENSE AGREEMENT This Amendment No. 2 to License Agreement (this ?Amendment?), dated as of December 27, 2022, is made by and between Relmada Therapeutics, Inc., a Nevada corporation (?Licensee?) and Dr. Charles E. Inturrisi, an individual, and Dr. Paolo Manfredi, an individual, jointly and severally (collectively, ?Licensor?). Whereas, the parties have previously e |
|
| December 28, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2022 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commiss |
|
| December 20, 2022 |
RLMD / Relmada Therapeutics Inc / KOTLER KEVIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 7, 2022 |
Exhibit 99.2 Reliance I Topline REL - 1017 for Major Depressive Disorder (MDD) Dec 07, 2022 Nasdaq: RLMD EXHIBIT 99.2 ©2022 Relmada All rights reserved Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may |
|
| December 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissi |
|
| December 7, 2022 |
Exhibit 99.1 Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder Company to Host Conference Call Today, December 7, 2022, at 5:00 PM ET CORAL GABLES, Fla., December 7, 2022 /PRNewswire/ - Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central ner |
|
| November 14, 2022 |
Exhibit 99.1 Targeting Major Advances in Treatment of CNS Disorders November 11th , 2022 I Nasdaq: RLMD 1 Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the ?Company?), along with certain statements that may be made by management of the Company orally in presenting this material, may contain ?forward - lookin g statements.? These |
|
| November 14, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2022 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commiss |
|
| November 10, 2022 |
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results Exhibit 99.1 Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results CORAL GABLES, Fla., Nov. 10, 2022 /PRNewswire/ - Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the three a |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commiss |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000- 55347 RELMADA THERAP |
|
| October 21, 2022 |
RLMD / Relmada Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 17, 2022 |
RLMD / Relmada Therapeutics Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Relmada Therapeutics, Inc. (Title of Class of Securities) Common Stock, $0.001 Par Valu |
|
| October 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Relmada Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.001 per share (the “Shares”) (Title of Class of Securities) 75955J402 |
|
| October 17, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| October 17, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Relmada Therapeutics, Inc., a Nevada corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the unders |
|
| October 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissi |
|
| October 13, 2022 |
Exhibit 99.1 Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder RELIANCE I and II Adjunctive MDD Trials Continue to Advance CORAL GABLES, Fla., Oct. 13, 2022 /PRNewswire/ - Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous |
|
| September 23, 2022 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| September 23, 2022 |
RLMD / Relmada Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Relmada Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 75955J 402 (CUSIP Number) September 16, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| September 22, 2022 |
Exhibit 10.1 September 21, 2022 Relmada Therapeutics, Inc. 2222 Ponce de Leon, Floor 3 Coral Gables, FL 33134 Re: Section 3(a)(9) Exchange Agreement Ladies and Gentlemen: This letter agreement (the ?Agreement?) confirms the agreement of Relmada Therapeutics, Inc., a Nevada corporation (the ?Company?), and the holders of the Common Stock listed on Schedule I attached hereto (the ?Stockholders?), pu |
|
| September 22, 2022 |
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [*] (subject to adjustment) Warrant No. [*] Original Issue Date: September 21, 2022 Relmada Therapeutics, Inc., a Nevada corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [HOLDER]. or its registered assigns (the ?Hold |
|
| September 22, 2022 |
Exhibit 3.1 |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2022 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commis |
|
| September 20, 2022 |
Exhibit 99.1 Relmada Therapeutics Announces Completion of Treatment in Company?s Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder CORAL GABLES, Fla., September 20, 2022 /PRNewswire/ - Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the completi |
|
| September 20, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commis |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000- 55347 Relmada Therapeutic |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission F |
|
| June 1, 2022 |
Relmada Therapeutics, Inc. 2021 Equity Incentive Plan, as amended. EXHIBIT 10.1 Relmada Therapeutics, Inc. 2021 EQUITY INCENTIVE PLAN (AS AMENDED) As adopted by the Board of Directors of Relmada Therapeutics, Inc., on March 19, 2021. As approved by the shareholders of Relmada Therapeutics, Inc., on May 20, 2021. As amended by the Board of Directors of Relmada Therapeutics, Inc., March 18, 2022. As approved by the shareholders of Relmada Therapeutics, Inc., on May |
|
| May 5, 2022 |
Exhibit 99.2 T a r g e t ing Major Advances in Treatment of CNS Disorders May 5th, 2022 I Nasdaq: RLMD 1 Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the ?Company?), along with certain statements that may be made by management of the Company orally in presenting this material, may contain ?forward - looking statements.? These st |
|
| May 5, 2022 |
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results Exhibit 99.1 Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results CORAL GABLES, Fla., May 5th, 2022 /PRNewswire/ - Relmada Therapeutics, Inc. (Nasdaq: RLMD) (?Relmada,? the ?Company,? ?we,? ?us, ?our?), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary an |
|
| May 5, 2022 |
Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55347 RELMADA THERAPEUTIC |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 7, 2022 |
As filed with the Securities and Exchange Commission on April 7, 2022 As filed with the Securities and Exchange Commission on April 7, 2022 Registration No. |
|
| April 7, 2022 |
Exhibit 1.2 Execution Version OPEN MARKET SALE AGREEMENTSM April 7, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Relmada Therapeutics, Inc., a Nevada corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the |
|
| April 7, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 Registration Statement under the Securities Act of 1933 (Form Type) Relmada Therapeutics, Inc. |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Commission file number: 000-55347 Relmada Therapeutics, Inc. (Exact name of registrant as specified in its c |
|
| March 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission |
|
| March 23, 2022 |
Exhibit 99.1 Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results CORAL GABLES, Fla., March 23, 2022 /PRNewswire/ - Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results |
|
| March 7, 2022 |
Exhibit 99.1 Targeting Major Advances in Treatment of CNS Disorders March 7, 2022 I Nasdaq: RLMD 1 Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the ?Company?), along with certain statements that may be made by management of the Company orally in presenting this material, may contain ?forward - lookin g statements.? These stateme |
|
| March 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commission |
|
| February 23, 2022 |
Exhibit 99.2 Human Abuse Potential (HAP) Study of REL - 1017 vs. Ketamine February 23, 2022 I Nasdaq: RLMD 1 Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the ?Company?), along with certain statements that may be made by management of the Company orally in presenting this material, may contain ?forward - lookin g statements.? The |
|
| February 23, 2022 |
Exhibit 99.1 Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential - All doses of REL-1017, including the maximum tolerated dose, demonstrated a statistically significant difference in abuse potential vs. ketamine (p-values <0.05) - All doses of REL-1017, including the maximum tolerated dose, were statistically equivalent to placebo (p-values |
|
| February 23, 2022 |
Exhibit 99.3 Targeting Major Advances in Treatment of CNS Disorders February 23, 2022 I Nasdaq: RLMD 1 D i sc l o s u r e s Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the ?Company?), along with certain statements that may be made by management of the Company orally in presenting this material, may contain ?forward - looking statements.? T |
|
| February 23, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commiss |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Relmada Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 75955J402 (CUSIP Number) March 26, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Relmada Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 75955J402 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pur |
|
| February 11, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Relmada Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 75955J402 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pur |
|
| February 3, 2022 |
RLMD / Relmada Therapeutics Inc / BlackRock Inc. Passive Investment us75955j4022020322.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) RELMADA THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 75955J402 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| December 22, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2021 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commiss |
|
| December 22, 2021 |
Exhibit 99.1 Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry - Manuscript further details findings from study assessing REL-1017 as adjunctive treatment for MDD - Primary endpoint results included rapid, significant, and sustained efficacy vs. placebo - Safety analysis showed adverse event profile comparable to placebo, with no sig |
|
| December 20, 2021 |
RLMD / Relmada Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Relmada Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 75955J402 (CUSIP Number |
|
| December 20, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2021 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commiss |
|
| December 20, 2021 |
Corporate Presentation dated December 20, 2021 Exhibit 99.1 |
|
| December 20, 2021 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated December 20, 2021 with respect to the shares of Common Stock, $0.001 par value per share of Relmada Therapeutics, Inc., a Nevada corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in ac |
|
| December 20, 2021 |
RLMD / Relmada Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Relmada Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 75955J402 (CUSIP Number) December 9, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| December 13, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2021 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissi |
|
| December 13, 2021 |
Exhibit 1.1 EXECUTION VERSION 8,823,530 Shares RELMADA THERAPEUTICS, INC. UNDERWRITING AGREEMENT December 8, 2021 GOLDMAN SACHS & CO. LLC JEFFERIES LLC As Representatives of the several Underwriters c/o GOLDMAN SACHS & CO. LLC 200 West Street New York, NY 10282 c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. Relmada Therapeutics, Inc., a Nevada cor |
|
| December 10, 2021 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-245054 PROSPECTUS SUPPLEMENT (to Prospectus dated August 21, 2020) 8,823,530 Shares Common Stock We are offering 8,823,530 of shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol ?RLMD.? On December 8, 2021, the last reported sale price of our common stock on The Nasdaq Global Select Market |
|
| December 8, 2021 |
Subject to Completion, Dated December 8, 2021 Filed Pursuant to Rule 424(b)(5) Registration No. 333-245054 The information contained in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these sec |
|
| December 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2021 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissi |
|
| December 7, 2021 |
Relmada Therapeutics, Inc. Poster Presentation Exhibit 99.1 |
|
| November 23, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2021 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commiss |
|
| November 23, 2021 |
Exhibit 99.1 Targeting Major Advances in Treatment of CNS Disorders November 23, 2021 I Nasdaq: RLMD 1 Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the ?Company?), along with certain statements that may be made by management of the Company orally in presenting this material, may contain ?forward - lookin g statements.? These sta |
|
| November 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commiss |
|
| November 15, 2021 |
Exhibit 99.1 Targeting Major Advances in Treatment of CNS Disorders November 2021 I Nasdaq: RLMD 1 Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the ?Company?), along with certain statements that may be made by management of the Company orally in presenting this material, may contain ?forward - looking statements.? These sta teme |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000- 55347 RELMADA THERAP |
|
| October 7, 2021 |
Exhibit 99.1 Relmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-Stage Clinical Program for REL-1017 for Treatment of Major Depressive Disorder Relmada is actively enrolling patients in RELIANCE III, a Monotherapy Registrational Phase 3 Study FDA Confirms Relmada Not Required to Conduct Two-Year Carcinogenicity Study and TQT Cardiac Study in Humans to Support Potential |
|
| October 7, 2021 |
Exhibit 99.2 Targeting Major Advances in Treatment of CNS Disorders October 2021 I Nasdaq: RLMD 1 Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the ?Company?), along with certain statements that may be made by management of the Company orally in presenting this material, may contain ?forward - looking statements.? These sta temen |
|
| October 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2021 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-39082 45-5401931 (State or other jurisdiction of incorporation) (Commissio |
|
| August 10, 2021 |
Exhibit 10.2 Certain information identified by [***] has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. LICENSE AGREEMENT BETWEEN RELMADA THERAPEUTICS, INC. AND ARBORMENTIS, LLC 1 LICENSE AGREEMENT This agreement (?Agreement?) is entered into as of July 16, 2021 (the ?Effective Date?), by and between Arbormentis |
